osw 1 has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Q; Li, S; Liao, M; Ma, H; Wu, M; Wu, X; Xi, H; Xia, Y; Zhang, Y | 1 |
| Ding, X; Li, J; Li, Y; Yin, Y | 1 |
2 other study(ies) available for osw 1 and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Mice; Phosphatidylinositol 3-Kinases; Triple Negative Breast Neoplasms | 2022 |
OSW-1 inhibits tumor growth and metastasis by NFATc2 on triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cholestenones; Disease Models, Animal; Female; Humans; Mice; Mice, SCID; Neoplasm Metastasis; NFATC Transcription Factors; Ornithogalum; Saponins; Triple Negative Breast Neoplasms | 2020 |